Elevated Cancer Markers: Prognosis and Survival Insights - Oncology

Share to:

Blood test?


My father has metastatic colorectal cancer that has spread to the liver.
Initially, in November of last year, his cancer marker was only 3.
Since then, he has undergone three surgeries for colorectal cancer and has not had the opportunity for chemotherapy, resulting in a dramatic increase to over 4800.
How long can he live with a cancer marker of over 4800? The attending physician said he only has three months to live.

vxv, 20~29 year old female. Ask Date: 2010/07/29

Dr. Chen Junyi reply Oncology


It should refer to the recurrence rate of tumors, which should be viewed from a relative personal perspective.

Reply Date: 2010/07/29

More Info


I'm sorry to hear about your father's situation. Elevated cancer markers, such as CEA (Carcinoembryonic Antigen), can provide some insight into the progression of cancer and the effectiveness of treatment, but they are not definitive indicators of prognosis on their own.
In your father's case, the significant rise in CEA levels from 3 to over 4800 ng/mL is concerning and suggests that the cancer is likely progressing. CEA is often used as a tumor marker for colorectal cancer, and high levels can indicate the presence of cancer, recurrence, or metastasis. However, it's important to note that CEA levels can also be influenced by other factors, including smoking, inflammation, and other medical conditions.
The prognosis for someone with metastatic colorectal cancer, especially when it has spread to the liver, can vary widely based on several factors, including the extent of the disease, the patient's overall health, response to any treatments, and specific characteristics of the cancer itself. Unfortunately, when cancer has metastasized and is not responding to treatment, the prognosis can be quite poor.
Your doctor’s estimate of three months may be based on clinical experience and the current state of your father's health, but it's essential to remember that these are estimates and can vary significantly from person to person. Some patients may live longer than expected, while others may have a shorter time.
In terms of what can be done, it may be worth discussing with your father's healthcare team about palliative care options. Palliative care focuses on providing relief from the symptoms and stress of the illness, improving quality of life, and supporting the patient and family during this challenging time.
Additionally, if your father has not yet undergone chemotherapy, it might be worth discussing the potential benefits and risks with his oncologist. Even in advanced stages, some patients may benefit from chemotherapy or targeted therapies, depending on the specific characteristics of their cancer.

It's also crucial to have open and honest conversations with the healthcare team about your father's wishes and goals of care. This can help ensure that he receives the support and treatment that aligns with his values and preferences.

In summary, while elevated cancer markers like CEA can indicate disease progression, they are just one piece of the puzzle. Prognosis can vary widely, and it's essential to have ongoing discussions with the healthcare team to understand the best options for your father's care. Please take care of yourself and your family during this difficult time.

Similar Q&A

Understanding Fluctuations in Cancer Markers: A Case Study on Liver Cancer

The blood cancer marker for liver cancer was over 500 during the May check-up (indicating metastasis from colon cancer to the liver), then it rose to 4800 during the June check-up (which was conducted before an emergency surgery due to a stroke in the colon), and dropped to 260 i...


Dr. Chen Junyi reply Oncology
It is likely due to changes in the tumor condition.

[Read More] Understanding Fluctuations in Cancer Markers: A Case Study on Liver Cancer


Understanding Cancer Markers: Insights on Stage 3B Rectal Cancer

Dear Doctor: For a patient with stage 3B sigmoid colon cancer, after surgery, the cancer marker level decreased from over 50 to around 4. Is this a significant reduction? I understand that cancer markers are not always accurate, but a decrease is still a positive outcome, right?


Dr. Lai Yicheng reply Oncology
Hello Huang Xiaomei: The current clinical application of tumor markers is primarily for monitoring treatment. The interpretation of elevated markers helps determine whether patients' levels return to normal after surgery, radiation, or chemotherapy, and whether they rise aga...

[Read More] Understanding Cancer Markers: Insights on Stage 3B Rectal Cancer


Managing Rising Cancer Markers: Treatment Options for Advanced Pancreatic Cancer

Hello, my father was diagnosed with stage IV pancreatic cancer in December, with vascular involvement making surgery impossible. His CA19-9 level is 340, and he has completed a regimen of 7 days of chemotherapy followed by 1 week off, and will continue with a regimen of 3 weeks o...


Dr. Hu Ziren reply Oncology
It is recommended to discuss with the attending physician for more appropriate guidance!

[Read More] Managing Rising Cancer Markers: Treatment Options for Advanced Pancreatic Cancer


Understanding T15 Tumor Marker Test Results: Next Steps for Patients

Hello Doctor, I recently underwent a T15 tumor marker test, and the results showed two markers exceeding the normal range. The first one is carbohydrate antigen CA72-4 with a result of 23.6, where the reference value is <5.3 U/ml. The second one is tumor marker CA125 with a re...


Dr. Lin Zongzhe reply Oncology
Hello! The interpretation of serum tumor markers often requires correlation with medical history and other clinical examinations to be meaningful. Many benign non-tumor diseases or even normal individuals may occasionally exhibit slight elevations in tumor markers. You may inquir...

[Read More] Understanding T15 Tumor Marker Test Results: Next Steps for Patients


Related FAQ

Cancer

(Oncology)

Cancer Screening

(Oncology)

Blood

(Oncology)

Blood Test Report

(Oncology)

Colon Cancer

(Oncology)

Lymph Node Cancer

(Oncology)

Pancreatic Cancer

(Oncology)

Cea Index

(Oncology)

Nasopharyngeal Cancer

(Oncology)

Liver Cancer

(Oncology)